

Special Issue

Challenges and Future Trends of COVID-19 Vaccination

Message from the Guest Editor

During 2020 and 2021, a combination of supply shortages, manufacturing challenges, intense competition for vaccines, export bans, and delays to regulatory approvals has meant that many low- and lower-middle income countries were left behind as deliveries of COVID-19 vaccines increased in higher-income countries. While some high-income countries have vaccinated more than 70% of their population, many LMICs has vaccinated less than their 10% populations so far. We are pleased to invite you to submit your original manuscripts, reviews, position papers, and case studies which discuss implementation, surveillance, research, programs of COVID-19 vaccination, policies related to COVID-19 vaccination, and social and behavioral science strategies supporting vaccine acceptance. We especially welcome submissions exploring vaccination amongst diverse and marginalized communities that have been acutely affected by the COVID-19 pandemic. Submissions dealing with lessons learned from the past and current health crises relating to pandemic preparedness in the future will also be considered. We look forward to receiving your contributions.

Guest Editor

Dr. Imran Raza Mirza
UNICEF, New York, NY 10017, USA

Deadline for manuscript submissions

closed (31 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/118576

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).